CHD: Bearish Downtrend Signals Potential Put Option Play

The company develops, manufactures, and markets a variety of consumer household and personal care products, as well as specialty products focused on animal and food production, chemicals, and cleaners. Key brands include 'ARM & HAMMER' (baking soda, cat litter, laundry detergent), 'OXICLEAN' (stain removers, cleaning solutions), 'VITAFUSION' and 'L’IL CRITTERS' (gummy dietary supplements), 'BATISTE' (dry shampoo), 'WATERPIK' (water flossers and showerheads), 'THERABREATH' (oral care), 'HERO' (acne treatment), and 'TROJAN' (condoms). These products are sold through supermarkets, mass merchandisers, wholesale clubs, drugstores, and e-commerce channels to consumers, and specialty products are sold to industrial customers and livestock producers. The company operates through Consumer Domestic, Consumer International, and a Specialty Products Division. The business strategy centers on product innovation, brand recognition, and offering value. The company also emphasizes sustainability and responsible sourcing.

No relevant news was found for this stock today.

CHD's technical outlook is bearish, evidenced by a persistent downtrend over the past 90 days. The stock price has declined from approximately $98 in late July to $86.60 as of November 4, 2025. The price is trading below its 50-day SMA (90.23) and well below the 200-day SMA (97.77), confirming the downtrend. Momentum indicators support this bearish view; the MACD is negative (-1.176), and the RSI is 47.65, indicating neither overbought nor oversold conditions but trending downward. The ADX at 17.57 suggests the downtrend has some strength, although not excessively strong. Furthermore, the Stochastic Oscillator shows STOCHk at 47.03, with STOCHd at 25.83, suggesting a potential for further downside. The recent price action shows a lack of sustained upward movement, with lower highs and lower lows dominating the chart. Given these factors, the technical indicators suggest a continued bearish trend for CHD over the next 1–3 months, with potential for further declines.

The company presents a mixed financial picture. For the three months ended September 30, 2025, 'Net Sales' increased by 5.0% to $1,585.6 compared to the prior year. However, the 'Gross Profit' margin decreased slightly by 10 basis points to 45.1%. For the nine months ended September 30, 2025, 'Net Sales' increased by a modest 0.7% to $4,559.0, while the 'Gross Profit' margin decreased more significantly by 170 basis points to 44.3%. 'Net cash provided by operating activities' for the nine months ended September 30, 2025, decreased by $11.9 to $852.0 compared to $863.9 in the same period in 2024, due to an increase in working capital. The company anticipates that its cash from operations and borrowing capacity will be sufficient to fund share repurchases, debt payments, dividends, and capital expenditure programs, which are expected to be approximately $120.0 in 2025. The company is also exiting the Flawless, Spinbrush and Waterpik showerhead businesses, expecting to complete this by early 2026, which generated approximately $170.0 of annual 'Net Sales' in 2024. They are also performing a strategic review of their vitamin business. They completed the acquisition of Touchland on July 16, 2025 for $656.4, net of cash acquired.

The Church & Dwight Q2 2025 earnings call strikes a moderately bullish tone, driven by performance exceeding initial expectations, though tempered by ongoing economic uncertainty. CEO Richard Dierker noted that organic sales grew 0.1%, surpassing their outlook of -2% to flat. Management's sentiment is captured by the statement that Q2 sales 'finished slightly ahead of our outlook,' boosting confidence in achieving the full-year organic outlook of 0% to 2%. Despite adjusted gross margin decreasing by 40 basis points, adjusted EPS of $0.94 exceeded the $0.85 outlook. The company also highlights strategic actions, including the acquisition of Touchland, which is expected to be accretive, and ongoing efforts to revitalize the vitamin business, showing 'green shoots' in the multivitamin segment. While challenges persist, such as retail destocking and gummy vitamin consumption declines, the company emphasizes its balanced portfolio, innovation, and international growth, all contributing to a cautiously optimistic outlook.

CHD's financial performance presents a somewhat positive but mixed picture. Revenue has shown a slight upward trend, starting from $1503.3M in Q1 2024 and reaching $1585.6M in Q3 2025, indicating some top-line growth. However, the gross profit ratio has fluctuated, peaking at 0.471 in Q2 2024 and settling at 0.451 in Q3 2025, suggesting inconsistent profitability. Operating cash flow has been generally positive, with $435.5M in the latest quarter (Q3 2025), indicating the company is generating cash from its operations. Total debt has remained relatively stable, fluctuating between $2.404B and $2.419B throughout 2024 and decreasing to $2.204B in Q3 2025, suggesting a slight improvement in the company's solvency. Overall, while revenue is growing and operating cash flow is healthy, the fluctuating gross profit ratio warrants attention. The decrease in total debt is a positive sign, but the company needs to maintain consistent profitability and cash generation to ensure long-term financial health.

The company demonstrates a moderately bullish profile, characterized by solid revenue growth and improving profitability. Revenue has consistently increased, indicating strong market demand. The gross margin exhibits stability, suggesting effective cost management. Return on Equity (ROE) has improved, showcasing efficient capital allocation. While the Price-to-Earnings (P/E) ratio is elevated, it is potentially justified by the company's growth prospects. The Debt-to-Equity ratio has decreased, reflecting a healthier balance sheet and reduced financial risk. The current ratio is at a healthy level, implying sufficient liquidity to meet short-term obligations. Overall, the company presents a favorable combination of growth, profitability, and balance sheet strength, supporting a positive outlook for the next 12 months, although the high P/E ratio warrants close monitoring.